Patents Issued in July 2, 2020
  • BACTERIAL POPULATIONS FOR PROMOTING HEALTH
    Publication number: 20200206283
    Abstract: A method of improving the glucose response in glucose tolerant and intolerant subjects is provided. The method comprises providing to the subject probiotic compositions, or agents which specifically reduce bacterial species.
    Type: Application
    Filed: November 14, 2019
    Publication date: July 2, 2020
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Eran SEGAL, Eran ELINAV
  • TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION
    Publication number: 20200206284
    Abstract: Provided herein are compositions and methods for the treatment or prevention of pathogenic infections.
    Type: Application
    Filed: December 4, 2019
    Publication date: July 2, 2020
    Applicant: Vedanta Biosciences, Inc.
    Inventors: Jessica Schneider, Yun-Gi Kim, Bernat Olle, Shilpa Reddy, Jason Norman, Juan Patarroyo
  • ONCOLYTIC VIRAL VECTORS AND USES THEREOF
    Publication number: 20200206285
    Abstract: The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle.
    Type: Application
    Filed: July 26, 2018
    Publication date: July 2, 2020
    Inventors: Mitchell H. FINER, Lorena LERNER, Christophe QUÉVA, Edward KENNEDY
  • REPLICATION-COMPETENT VESICULAR STOMATITIS VIRUSES
    Publication number: 20200206286
    Abstract: This document provides methods and materials related to vesicular stomatitis viruses. For example, replication-competent vesicular stomatitis viruses, nucleic acid molecules encoding replication-competent vesicular stomatitis viruses, methods for making replication-competent vesicular stomatitis viruses, and methods for using replication-competent vesicular stomatitis viruses to treat cancer or infectious diseases are provided.
    Type: Application
    Filed: March 3, 2020
    Publication date: July 2, 2020
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Kah-Whye Peng, Stephen James Russell, Camilo Ayala Breton
  • Method and Compositions for Treating Viral Infection
    Publication number: 20200206287
    Abstract: A method of treating viral infection, such as viral infection caused by a virus of the Filoviridae family, Flaviviridae family (Flavivirus genus), Deltaretrovirus genus, or Togaviriade family is provided. A composition having at least one cardiac glycoside is used to treat viral infection. The composition can further include at least one triterpene. Alternatively, the composition comprises at least one, at least two, or at least three triterpenes.
    Type: Application
    Filed: February 27, 2020
    Publication date: July 2, 2020
    Applicant: PHOENIX BIOTECHNOLOGY, INC.
    Inventors: Robert A. NEWMAN, Otis C. ADDINGTON
  • Method and Compositions for Treating Viral Infection
    Publication number: 20200206288
    Abstract: A method of treating viral infection, such as viral infection caused by a virus of the Filoviridae family, Flaviviridae family (Flavivirus genus), Deltaretrovirus genus, or Togaviriade family is provided. A composition having at least one cardiac glycoside is used to treat viral infection. The composition can further include at least one triterpene. Alternatively, the composition comprises at least one, at least two, or at least three triterpenes.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Applicant: PHOENIX BIOTECHNOLOGY, INC.
    Inventors: Robert A. NEWMAN, Otis C. ADDINGTON
  • COMPOSITION FOR PROMOTING PERIODONTAL REGENERATION
    Publication number: 20200206289
    Abstract: The present invention relates to a composition for promoting periodontal regeneration. The composition for promoting periodontal regeneration according to the present invention includes any one dicotyledon extract belonging to the order Campanula punctata, selected from the group consisting of Ussuri thistle extract, Helianthus annuus extract, Dandelion extract, Chrysanthemum extract, Arctium lappa extract, Common cosmos extract, Ligularia stenocephala extract, Foremost mugwort extract, Cichorium intybus extract, and mixture thereof.
    Type: Application
    Filed: November 21, 2017
    Publication date: July 2, 2020
    Inventors: Ji Won LEE, Yoo Hun NOH
  • COMPOSITIONS INCLUDING MILK THISTLE AND METHODS OF USE
    Publication number: 20200206290
    Abstract: In an embodiment, the present disclosure pertains to a dietary supplement including berberine in an amount up to about 1500 mg, cinnamon in an amount up to about 300 mg, chromium in an amount up to about 300 mcg, milk thistle in an amount up to about 150 mg, and pyrroloquinoline quinone disodium (PQQ) in an amount up to about 30 mg. Additionally, the present disclosure relates to a method for managing weight, maintaining healthy blood sugar levels, preventing diabetes, or alleviating symptoms associated with diabetes, including administering a composition to a subject. In some embodiments, the composition includes berberine in an amount up to about 1500 mg, cinnamon in an amount up to about 300 mg, chromium in an amount up to about 300 mcg, milk thistle in an amount up to about 150 mg, and PQQ in an amount up to about 30 mg.
    Type: Application
    Filed: December 31, 2019
    Publication date: July 2, 2020
    Inventor: Odes W. Mitchell
  • COMPOSITION FOR PREVENTING OR TREATING OBESITY, COMPRISING SUPPLEMENT FOR REDUCING BODY FAT AND B-GLUCAN AS ACTIVE INGREDIENTS
    Publication number: 20200206291
    Abstract: The present invention relates to a composition for preventing or treating obesity, comprising a supplement for reducing body fat and a ?-glucan as active ingredients.
    Type: Application
    Filed: August 29, 2018
    Publication date: July 2, 2020
    Applicant: QUEGEN BIOTECH CO., LTD.
    Inventors: Jong Dae LEE, Je Phil RYOO, Seung In CHOI, Je Kyoung KIM, Yong Man JANG, Min Ji KIM, Eun Ji PARK, Chul Su YANG
  • Compositions and Methods for Managing or Improving Bone Disorders, Joint Disorders, Cartilage Disorders, or a Combination Thereof
    Publication number: 20200206292
    Abstract: Compositions and methods for bone health, cartilage health or both, are disclosed that include preparing and utilizing a mixture of at least one Morus extract enriched for one or more prenylated flavonoids, at least one Scutellaria extract enriched for one or more free-B-ring flavonoids, and at least one Acacia extract enriched for one or more flavans.
    Type: Application
    Filed: March 9, 2020
    Publication date: July 2, 2020
    Applicant: Unigen, Inc.
    Inventors: Qi Jia, Ping Jiao, Mesfin Yimam, Teresa Horm
  • METHOD FOR ENHANCING NITRIC OXIDE LEVELS IN A USER
    Publication number: 20200206293
    Abstract: A method for enhancing the nitric oxide levels in a user. Nitric oxide can provide many benefits to a user including, but not limited to, improved sleeping quality, regulation of blood pressure, and strengthening of the immune system. A quantity of bacopa monnieri and a quantity of consumable produce is heterogeneously combined together into a supplement mixture. A daily dosage of the supplement mixture is administered to a user daily in order enhance the nitric oxide levels of the user. The enhancement of nitric oxide levels provides many benefits as mentioned previously and additional benefits such as, but not limited to, increasing brain function and improving memory.
    Type: Application
    Filed: September 19, 2019
    Publication date: July 2, 2020
    Inventor: Chinni Krishnan RAJKUMAR
  • ALOE-HYPLEX TOPICAL FORMULATION AND A METHOD OF PREPARATION
    Publication number: 20200206294
    Abstract: The present invention relates to aloe-hyplex topical formulation and a method of preparation for multilayer skin delivery of active ingredients to provide skin rejuvenating effect. The aloe-hyplex formulation comprises of: a) Aloe vera leaf extract in the range of 5-15% by wt., b) at least one anti-inflammatory agent in the range of 5-15% by wt., c) sodium hyaluronate in the range of 0.001-0.1% by wt., d) glycerin in the range of 50-85% by wt., and e) water in the range of 0.5-5% by wt. The method of preparation of the formulation comprises of mixing and stirring the Aloe vera extract, anti-inflammatory agent, sodium hyaluronate, glycerin and water to obtain a homogenous aloe-hyplex formulation.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Inventor: Cherylanne DeVita
  • Burn Remedy
    Publication number: 20200206295
    Abstract: The use any type of coconut oil immediately on a burn site following a burn incident, reduce and/or resolve the burning pain, and prevent skin blistering. Positive outcome is dependent on time lapse between burn occurrence and coconut oil application. For best result apply any type of coconut oil to the burn site immediately; but will still reduce the burning pain even if time has lapsed and blistering already occurred. A combination of application of cold water first then any coconut oil to a burn site immediately following burn injury reduced healing time.
    Type: Application
    Filed: December 20, 2019
    Publication date: July 2, 2020
    Inventor: Uzoaku Chukwu
  • TRADITIONAL CHINESE MEDICINE COMPOSITION FOR PROTECTING JOINTS, METHOD FOR PRODUCING THE SAME AND USE THEREOF
    Publication number: 20200206296
    Abstract: The present invention relates to the field of health care food technology, specifically to a traditional Chinese medicine composition with a function of protecting joints, a use thereof, a method for producing the same and a health care food thereof. The Chinese medicine composition comprises CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract. The composition of the present disclosure has a reasonable formulation, and the ingredients cooperate with each other to achieve functions of reducing arthrocele degree, decreasing arthritis index, ameliorating biochemical index of arthritis and reducing articular cavity area through various paths and at various levels.
    Type: Application
    Filed: May 17, 2019
    Publication date: July 2, 2020
    Applicant: INFINITUS (CHINA) COMPANY LTD.
    Inventors: Liugang DING, Zhongbao YUE, Danlin HE, Yong ZHOU, Jian TANG
  • COMPOSITIONS AND METHODS FOR TREATMENT OF ALCOHOL INDUCED LIVER INJURY
    Publication number: 20200206297
    Abstract: Methods for treating alcohol induced liver injury include administering to a subject an effective amount of a ginger-derived nanoparticle. Methods for decreasing nuclear factor erythroid-2 related factor (Nrf2) activation in a hepatocyte are also provided and include contacting the hepatocyte with an effective amount of a ginger-derived nanoparticle. Pharmaceutical preparations including ginger-derived nanoparticles are further provided.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Applicant: University of Louisville Research Foundation, Inc.
    Inventor: Huang-Ge Zhang
  • LISINOPRIL FORMULATIONS
    Publication number: 20200206298
    Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
    Type: Application
    Filed: September 9, 2019
    Publication date: July 2, 2020
    Inventors: Gerold L. MOSHER, David W. MILES
  • INHIBITORS OF BETA-ARRESTIN-NEUROKININ 1 RECEPTOR INTERACTIONS FOR THE TREATMENT OF PAIN
    Publication number: 20200206299
    Abstract: The present invention relates to compounds and their uses. In particular, to compounds that inhibit the interaction between ?-arrestin and the intracellular C-terminus of the activated NK1R and their use in the treatment of pain.
    Type: Application
    Filed: February 23, 2017
    Publication date: July 2, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventor: Nigel Bunnett
  • AGENT FOR PROMOTING SKELETAL MUSCLE INJURY REPAIR
    Publication number: 20200206300
    Abstract: The present invention provides an agent for promoting skeletal muscle injury repair which agent comprises at least one peptide selected from the following (1) to (4): (1) a peptide consisting of the amino acid sequence of SEQ ID NO: 1, (2) a peptide consisting of the amino acid sequence of SEQ ID NO: 2, (3) a peptide consisting of the amino acid sequence of SEQ ID NO: 3, and (4) a peptide which is a human osteopontin fragment and has the amino acid sequence of SEQ ID NO: 1, 2, or 3 at the C-terminus, or a salt thereof as an active ingredient.
    Type: Application
    Filed: June 12, 2018
    Publication date: July 2, 2020
    Applicant: Osaka University
    Inventors: Susumu TANAKA, Mikihiko KOGO, Hirofumi YAMAMOTO, Naomasa KAWAGUCHI, Yoshinosuke HAMADA
  • JNK Inhibitor Molecules For Treatment Of Various Diseases
    Publication number: 20200206301
    Abstract: The present invention relates to the use of novel JNK inhibitor molecules and their use in a method of treatment of the human or animal body by therapy.
    Type: Application
    Filed: January 24, 2020
    Publication date: July 2, 2020
    Inventors: Jean-Marc COMBETTE, Catherine DELOCHE
  • USE OF DES-ASPARTATE-ANGIOTENSIN I TO TREAT PATIENTS EXHIBITING INFLAMMATORY DISEASES AND THEIR SYMPTOMS
    Publication number: 20200206302
    Abstract: The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I and/or its derivatives for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions.
    Type: Application
    Filed: February 24, 2020
    Publication date: July 2, 2020
    Applicant: SimPharma Pte Ltd
    Inventor: Meng Kwoon SIM
  • METHODS AND COMPOSITIONS FOR DETECTING AND TREATING ENDOMETRIOSIS
    Publication number: 20200206303
    Abstract: The present disclosure provides improved methods of providing endometriosis testing to patients, as well as improved methods of monitoring and adjusting endometriosis treatments.
    Type: Application
    Filed: February 21, 2020
    Publication date: July 2, 2020
    Inventors: Heather BOWERMAN, Hugh TAYLOR
  • METHODS AND COMPOSITIONS FOR EFFICIENT DELIVERY THROUGH MULTIPLE BIO BARRIERS
    Publication number: 20200206304
    Abstract: Mini nanodrugs that include a polymalic-based molecular scaffold with one or more peptides capable of crossing the blood-brain barrier, one or more plaque-binding peptides and one or more therapeutic agents attached to the scaffold are provided. Methods of treating brain diseases or abnormal conditions, and imaging of the same in a subject by administering the mini nanodrugs are described. Methods for reducing formation of amyloid plaques in the brain of a subject are disclosed.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Applicant: Cedars-Sinai Medical Center
    Inventors: Eggehard Holler, Julia Y. Ljubimova, Keith L. Black
  • Granular Pharmaceutical Composition
    Publication number: 20200206305
    Abstract: The present invention relates to a granular pharmaceutical composition obtained by coating a nucleus with: (1) a layer containing a material having a damp-proofing function, and (2) a drug layer containing linaclotide, a pharmaceutically acceptable salt, or a hydrate thereof, and (3) a layer containing a material having a damp-proofing function. Also, the present invention relates to a method for manufacturing the granular pharmaceutical composition obtained by coating the nucleus with (1) the layer containing the material having a damp-proofing function, (2) the drug layer containing the linaclotide, the pharmaceutically acceptable salt, or the hydrate thereof, and (3) the layer containing the material having a damp-proofing function.
    Type: Application
    Filed: March 12, 2020
    Publication date: July 2, 2020
    Inventors: Mare Nishiura, Kenichi Ashihara, Kanehira Imai, Atsushi Muro, Tsukasa Nishikawahara
  • SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND TWO OR MORE POLYLACTIDE-CO-GLYCOLIDE POLYMERS
    Publication number: 20200206306
    Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-coglycolide polymers (PLGAs).
    Type: Application
    Filed: March 10, 2020
    Publication date: July 2, 2020
    Inventors: Holger Petersen, Markus Ahlheim
  • COMPOSITIONS FOR INCREASING RESILIENCE TO TRAUMATIC BRAIN INJURY
    Publication number: 20200206307
    Abstract: Provided herein are methods, compositions, and uses thereof for preventing traumatic brain injury (TBI) in a subject, wherein a composition comprising whey protein isolate and/or whey protein concentrate may be administered to a subject pre-injury, thereby increasing resilience of the subject to TBI.
    Type: Application
    Filed: June 14, 2018
    Publication date: July 2, 2020
    Applicant: Immunotec Inc.
    Inventors: Elizabeth E. IGNOWSKI, Daniel A. LINSEMAN
  • SUPPRESSION OF ALLERGIC LUNG INFLAMMATION AND HYPERREACTIVITY
    Publication number: 20200206308
    Abstract: This disclosure relates to compositions of isolated polypeptides and methods of their use for the treatment and prevention of disease or disease symptoms associated with MARCKS phosphorylation and/or dissociation from the cell membrane, including but not limited to allergic inflammation, asthma, chronic bronchitis, COPD, infection, hyper-reactivity, cystic fibrosis, ulcerative colitis, Crohn's disease, irritable bowel syndrome, rosacea, eczema, psoriasis, acne, arthritis, rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus.
    Type: Application
    Filed: April 25, 2019
    Publication date: July 2, 2020
    Inventors: Reen Wu, Ching-Hsien Chen, Chen-Chen Lee
  • METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF NURR1- AND PPARy-MEDIATED CONDITIONS
    Publication number: 20200206309
    Abstract: Provided herein are methods and compositions for treating a Nurr1-mediated and/or PPAR-mediated condition. Also provided herein are methods and compositions for increasing Nurr1 or PPAR activity and/or levels in a cell.
    Type: Application
    Filed: July 27, 2018
    Publication date: July 2, 2020
    Inventors: Kwang-Soo Kim, Yongwoo Jang, Chun-Hyung Kim
  • HEMICHANNEL EXTRACELLULAR-DOMAIN SPECIFIC AGENTS FOR TREATING SEPSIS
    Publication number: 20200206310
    Abstract: Methods of treating sepsis or endotoxemia in a subject comprising administering to the subject an amount of an antagonist of a Panx1 hemichannel protein or an amount of an antagonist of a Cx43 hemichannel protein.
    Type: Application
    Filed: January 16, 2020
    Publication date: July 2, 2020
    Inventors: Haichao Wang, Wei Li, Kevin J. Tracey, Ping Wang
  • COMPOSITION INCLUDING MELITTIN FOR REMOVING M2-TYPE TUMOR-ASSOCIATED MACROPHAGE
    Publication number: 20200206311
    Abstract: The present invention relates to a composition including melittin as an active ingredient for removing an M2-type tumor-associated macrophage (TAM), and more specifically, the present invention relates to a composition exhibiting an effect of selectively suppressing only M2-type tumor-associated macrophages among tumor-associated macrophages. The composition according to the present invention only suppresses M2-type tumor-associated macrophages without affecting M1-type tumor-associated macrophages or cancer cells, thus exhibiting anti-cancer and metastasis suppressing effects by blocking angiogenesis through control of the microenvironment of cancer cells, while reducing the side-effects of existing anti-cancer effects.
    Type: Application
    Filed: April 30, 2018
    Publication date: July 2, 2020
    Applicant: LENUS LAB
    Inventors: Hyunsu BAE, Chan-Ju LEE
  • CHLOROTOXIN AGENTS AND USES THEREOF
    Publication number: 20200206312
    Abstract: The present invention provides, among other things, compositions and methods relating to detection and/or treatment cancer (e.g., one or more tumors) that expresses Neuropilin 1 (NRP1). The present invention provides methods of treating cancer that include administering a chlorotoxin agent to a subject (e.g., to a subject suffering from or susceptible to the cancer which may, in some embodiments, be a cancer that expresses NRP1). In some embodiments, a chlorotoxin agent for use in accordance with the present invention can be or comprise a chlorotoxin polypeptide and a payload moiety (e.g., as a covalent conjugate).
    Type: Application
    Filed: September 14, 2018
    Publication date: July 2, 2020
    Inventors: Sharon McGonigle, Utpal Majumder, Maarten H. D. Postema
  • POLYPEPTIDE NANOTUBES LINKED BY DISULFIDE BONDS FOR TARGETED DELIVERY OF CYTOTOXIC THERAPIES
    Publication number: 20200206313
    Abstract: Provided herein is a self-assembling polypeptide-based nanotube system having the ability to target cancer cells. The nanotubes target the cancer cell surface through integrin engagement with the help of multiple RGD units present along their surface and release their drug payload in a sustained manner. In addition, the nanotubes can be utilized for cellular imaging using any covalently tagged fluorescent dye. Provided herein is a self-assembling polypeptide-based nanotube system having the ability to target cancer cells. The nanotubes target the cancer cell surface through integrin engagement with the help of multiple RGD units present along their surface and release their drug payload in a sustained manner. In addition, the nanotubes can be utilized for cellular imaging using any covalently tagged fluorescent dye.
    Type: Application
    Filed: December 23, 2019
    Publication date: July 2, 2020
    Applicants: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT, INDIAN INSTITUTE OF SCIENCE
    Inventors: Steven A. ROSENZWEIG, Hanudatta S. ATREYA, Asampilli GITANJALI, Paturu KONDAIAH
  • HSV VECTORS FOR DELIVERY OF NT3 AND TREATMENT OF CIPN
    Publication number: 20200206314
    Abstract: Disclosed herein are compositions and methods for treating neuropathy, embodiments, HSV vectors are provided comprising nucleic acid molecules encoding neurotrophins, such as neurotrophin 3 (NT3).
    Type: Application
    Filed: March 24, 2017
    Publication date: July 2, 2020
    Applicant: PeriphaGen, Inc.
    Inventors: David M. Krisky, James B. Wechuck, James R. Goss
  • COMPOSITIONS AND METHODS COMPRISING BONE MORPHOGENETIC PROTEIN AND NEMO BINDING PEPTIDE
    Publication number: 20200206315
    Abstract: An osteogenic composition for implantation at or near a target tissue site beneath the skin is provided, the osteogenic composition comprising bone morphogenetic protein and a NEMO binding domain peptide, where the NEMO binding domain peptide reduces soft tissue inflammation at or near the target tissue site. In some embodiments, a method is provided for treating a target tissue site in a patient in need of such treatment, the method comprising implanting an osteogenic composition comprising bone morphogenetic protein and a NEMO binding domain peptide, where the NEMO binding domain peptide reduces soft tissue inflammation at or near the target tissue site.
    Type: Application
    Filed: December 19, 2019
    Publication date: July 2, 2020
    Inventors: Juliane Glaeser, Hyun Bae, Linda Kanim, Dmitriy Sheyn, Khosrowdad Salehi
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20200206316
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Applicant: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • COMPOSITIONS AND METHODS FOR INDUCED BROWN FAT DIFFERENTIATION
    Publication number: 20200206317
    Abstract: The invention provides methods and compositions for inducing brown fat cell differentiation through modulation of both Prdm16 and C/EBP? activity and/or expression. Also provided are methods for preventing or treating obesity or an obesity related disorder in a subject through stimulation of both Prdm16 and C/EBP? expression and/or activity. Further provided are methods for identifying compounds that are capable of modulating both Prdm16 and C/EBP? expression and/or activity.
    Type: Application
    Filed: December 19, 2019
    Publication date: July 2, 2020
    Inventors: Bruce M. Spiegelman, Shingo Kajimura
  • TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
    Publication number: 20200206318
    Abstract: The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
    Type: Application
    Filed: February 26, 2020
    Publication date: July 2, 2020
    Inventors: Miranda Chapman, Bruce Ewenstein, Bettina Ploder
  • METHOD FOR PREVENTING OR TREATING SEXUALLY TRANSMITTED INFECTIONS
    Publication number: 20200206319
    Abstract: Surfactant protein A (SP-A) is described for preventing and/or treating a sexually transmitted infection (STI) in a subject. The STI is caused by a DNA virus, such as Human papillomavirus (HPV) and/or Herpes simplex virus (HSV). SP-A can thus be used to prevent cervical cancer, genital warts and/or genital ulcers. Pharmaceutical compositions and kits comprising SP-A are also described, as is a method for preventing and/or treating STIs caused by DNA viruses, the method comprising administering an effective amount of SP-A to a subject in need thereof.
    Type: Application
    Filed: July 17, 2018
    Publication date: July 2, 2020
    Inventors: Georgia Schäfer, William Gordon Charles Horsnell, Howard William Clark
  • Oral Care Compositions
    Publication number: 20200206320
    Abstract: An oral care composition, including a catalyzing enzyme and an anhydrous matrix configured to at least partially stabilize the catalyzing enzyme, wherein the anhydrous matrix includes a source of hydrogen peroxide, an acyl donor, a non-aqueous anhydrous liquid, and a surfactant mixture including sodium lauryl sulfate (SLS), Betaine, and a poloxamer.
    Type: Application
    Filed: December 18, 2019
    Publication date: July 2, 2020
    Applicant: Colgate-Palmolive Company
    Inventors: Shaotang YUAN, Paloma PIMENTA, Dennis ONTUMI, Jennifer GRONLUND, Robert DICOSIMO, Sharon HAYNIE, Mark S. PAYNE
  • METHODS FOR TREATING AND PREVENTING NEUTROPHIL-DERIVED NET TOXICITY AND THROMBOSIS
    Publication number: 20200206321
    Abstract: Embodiments of the technology described herein are based upon the discoveries that neutrophil extracellular traps (NETs) provide a stimulus for thrombus formation and that NETs are present in stored blood products. Accordingly, some embodiments relate to methods of treating and preventing toxicity of NETs and thrombosis caused by NETs. Additional embodiments are directed towards methods of treating stored blood products to prevent transfusion-related injuries.
    Type: Application
    Filed: February 27, 2020
    Publication date: July 2, 2020
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Denisa D. Wagner, Tobias A. Fuchs, Simon De Meyer, Kimberly Martinod, Alexander Brill, Grace M. Thomas
  • TREATING CANCER WITH CAS ENDONUCLEASE COMPLEXES
    Publication number: 20200206322
    Abstract: The invention generally relates to compositions and methods for targeted delivery of a Cas endonuclease or nucleic acid encoding a Cas endonuclease to a fusion sequence in a cancer cell but not in a healthy cell of a subject. The Cas endonuclease or nucleic acid encoding the Cas endonuclease may be complexed with a guide RNA complementary to a fusion sequence identified based on differences between a mutated sequence obtained from a cancer cell and a wild-type sequence obtained from a healthy cell of the subject. For example, the Cas endonuclease may be a Cas9 and cut DNA or a Cas13a and cut RNA. The Cas endonuclease complexes may induce cell death or cancerous cells or cause other beneficial effects.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Inventor: Anthony P. Shuber
  • AN AGENT, A DEVICE AND A BLOOD-CIRCULATION SYSTEM FOR TREATING LYSOSOMAL STORAGE DISEASES, AND A METHOD FOR TREATING LYSOSOMAL STORAGE DISEASES
    Publication number: 20200206323
    Abstract: A therapeutic agent containing, as an effective component, a glycolytic enzyme which is different from a deficient protein of a patient with lysosomal storage disease as a subject and/or a glycolytic enzyme which does not have a mannose 6-phosphate moiety or a mannose moiety.
    Type: Application
    Filed: September 7, 2018
    Publication date: July 2, 2020
    Applicants: THE NEMOURS FOUNDATION, SEIKAGAKU CORPORATION
    Inventors: Shunji TOMATSU, Kazuki SAWAMOTO, Takehiko NAKAMURA, Ikue KITAZAWA, Hideyuki FUTATSUMORI
  • METHOD FOR REGULATING AND CONTROLLING GLP-1/GLP-1R AND DRUG
    Publication number: 20200206324
    Abstract: The present invention discloses the use of plasminogen to regulate GLP-1/GLP-1R and treat a GLP-1/GLP-1R-related condition.
    Type: Application
    Filed: June 19, 2018
    Publication date: July 2, 2020
    Inventor: Jinan Li
  • SYSTEMS AND METHODS FOR PREPARING A THROMBIN SERUM
    Publication number: 20200206325
    Abstract: A system for preparing a thrombin serum that can include a containment device, a cage received within the containment device, a cap attachable to the containment device, an inlet port configured to introduce a non-anti-coagulated autologous blood fluid into the containment device, and an outlet port. An activator, such as glass beads, can be present within the containment device.
    Type: Application
    Filed: March 9, 2020
    Publication date: July 2, 2020
    Applicant: ARTHREX, INC.
    Inventors: Christopher BARE, Abigail NABORS, Melissa TUCKER, Robert HARRISON
  • Clostridium Histolyticum Enzymes and Methods for the Use Thereof
    Publication number: 20200206326
    Abstract: The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Inventor: Wayne K. Herber
  • HIPPO PATHWAY DEFICIENCY REVERSES SYSTOLIC HEART FAILURE POST-INFARCTION
    Publication number: 20200206327
    Abstract: Embodiments of the disclosure include methods and compositions related to treating or reducing the severity or delaying the onset of one or more cardiac conditions in a mammal In particular embodiments, the compositions concern Park2 and its use for a cardiac medical condition. In specific cases, effective amounts of Park2 polynucleotide(s) and/or Park2 polypeptide(s) are provided to an individual in need thereof, including for heart failure, for example. The administration may be locally to the heart, for example.
    Type: Application
    Filed: September 6, 2018
    Publication date: July 2, 2020
    Inventors: James F. Martin, John Leach
  • COMPOSITIONS, METHODS AND USES OF ALPHA 1-ANTITRYPSIN FOR EARLY INTERVENTION IN BONE MARROW TRANSPLANTATION AND TREATMENT OF GRAFT VERSUS HOST DISEASE
    Publication number: 20200206328
    Abstract: Embodiments of the present invention relate to compositions and methods for treatment of subjects in need of or having a bone marrow transplant. Certain embodiments describe compositions and methods for treatment of conditions associated with bone marrow transplantations in a subject, for example, Graft versus Host Disease (GvHD) or bone marrow transplantation rejection. Some embodiments concern early or immediate bone marrow transplantation rejection. Certain embodiments relate to compositions and uses of alpha1-antitrypsin (?1-antitrypsin, AAT) and carboxyterminal peptide derivatives thereof and/or compositions and uses of serine protease inhibitors, immunomodulators or anti-inflammatory agent activity similar to that of AAT.
    Type: Application
    Filed: January 15, 2020
    Publication date: July 2, 2020
    Inventors: Charles A. Dinarello, Eli C. Lewis
  • NUCLEOTIDE SEQUENCE EXPRESSING AN EXOSOME-ANCHORING PROTEIN FOR USE AS VACCINE
    Publication number: 20200206329
    Abstract: The present invention concerns a nucleotide sequence expressing a fusion protein, said fusion protein comprising or consisting of an exosome-anchoring protein fused at its C-terminus with an antigen, or a DNA expression vector comprising said nucleotide sequence, for use as vaccine.
    Type: Application
    Filed: October 11, 2017
    Publication date: July 2, 2020
    Inventor: Maurizio Paolo Maria FEDERICO
  • PARTNER OF SLD FIVE 1 (PSF1)-DERIVED PEPTIDE
    Publication number: 20200206330
    Abstract: A Partner of Sld Five 1 (PSF1)-derived peptide that can induce a Cytotoxic T-Cell (CTL) response useful for a specific immunotherapy for cancer patients and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the present invention are described.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Inventors: Hidekazu TANAKA, Motofumi IGUCHI, Mari YOKOYAMA
  • AN IMMUNOGENIC COMPOSITION HAVING IMPROVED STABILITY, ENHANCED IMMUNOGENICITY AND REDUCED REACTOGENICITY AND PROCESS FOR PREPARATION THEREOF
    Publication number: 20200206331
    Abstract: An immunogenic composition comprising of Diphtheria toxoid antigen (D), tetanus toxoid (T) antigen, Hepatitis B surface antigen (HBsAg), inactivated whole-cell B. pertussis (wP) antigen, Haemophilus influenzae type B (Hib) capsular saccharide conjugated to a carrier protein, Inactivated Polio Virus (IPV) antigen and additionally one or more antigens and the method of preparing the same. A fully liquid combination vaccine, showing improved immunogenicity, reduced reactogenicity and improved stability. Improved methods of formaldehyde inactivation, improved adsorption profile of Diphtheria toxoid antigen (D), tetanus toxoid (T) antigen and Hepatitis B (HepB) surface antigen adsorbed individually onto aluminium phosphate adjuvant, minimum total aluminum content (Al3+) and optimized concentration of 2-phenoxyethanol (2-PE) as preservative.
    Type: Application
    Filed: July 13, 2018
    Publication date: July 2, 2020
    Inventors: Rakesh KUMAR, Inder Jit SHARMA, Anil Vyankatrao SHITOLE, Manohar DODDAPANENI, Hitt Jyoti SHARMA
  • COMPOSITIONS AND METHODS FOR INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER
    Publication number: 20200206332
    Abstract: Provided are methods for sensitizing gastrin-associated tumors and/or cancers in subjects to inducers of humoral and cellular immune responses. In some embodiments, the methods relate to administering compositions that have anti-gastrin antibodies, gastrin peptides, and/or nucleic acids that inhibit expression of gastrin gene products to subjects. Also provided are methods for preventing, reducing, and/or eliminating the formation of fibroses associated with tumors and/or cancers, and methods for treating gastrin-associated tumors and/or cancers that include administering to subjects in need thereof a first agent that provides and/or induces an anti-gastrin humoral or cellular immune response in the subject and a second agent that includes one or more stimulators of cellular immune responses against the tumors and/or cancers.
    Type: Application
    Filed: June 15, 2018
    Publication date: July 2, 2020
    Applicant: Cancer Advances Inc.
    Inventors: Lynda Sutton, Jill P. Smith, Nicholas Osborne, Brian E. Huber, Allen Cato